Skip to content
Sign in
SWC 2026 FinalistGrand Final: Lunch Block

Allergen Alert

bioMérieux spin-off miniaturising allergen testing into a pocket lab; strong backers, but still pre-product.

Lyon, France, EuropeAgri & FoodTech, Food allergen detection / food safetyFrance – Aix-en-Provence stage (Rencontres économiques d'Aix)
Stage
SeedNo documented AI
Product
PrototypeNone known
Funding raised
$3.9Mdisclosed
Founded
20242 years ago
Founders
2Bénédicte, Antoine
Global score
3.8Grade DRank 101 of 151

Overview

Lyon-based startup developing a “pocket laboratory” that quickly detects allergens in a dish or food.

Traction

None known

Portable mini-lab still in development (“early adopter” program, bioMérieux spin-off); no sales or customer pilot announced.

Market

Food allergen testing

Food allergen testing today is done in laboratories (ELISA, PCR) for manufacturers and regulators, too slow for a restaurant plate or a consumer meal. A portable test would open new buyers: restaurants and caterers managing liability, food brands verifying 'free-from' claims, and allergic consumers. Regulation (EU allergen labelling) and litigation risk drive demand, but consumer adoption depends on price per test and accuracy.

Addressable market

2025
$1B
2030
$1.4B
+7.4% a year

Food allergen testing: global market from $0.96bn in 2025 to $1.37bn in 2030 (CAGR 7.4%) according to Mordor Intelligence.

Customers

Allergic consumers and families; restaurants, caterers and food service; free-from food brands; food QA teams

Who signs the cheque

Food service operators and brands (B2B), consumers via pharmacy/retail (B2C)

Geographies

  • France
  • Europe

Drivers

  • Rising food allergy prevalence and labelling regulation
  • Liability of food service for undeclared allergens
  • Growth of free-from and medical-nutrition products

Headwinds

  • Accuracy and false-negative liability
  • Cost per consumable test vs consumer willingness to pay
  • Regulatory/clinical validation needs

Global food allergen testing market from $0.96bn in 2025 to $1.37bn in 2030 (CAGR 7.4%) according to Mordor Intelligence.

Scalability 5/10. Hardware mini-lab + consumables, replicable but subject to food regulatory approvals.

Market source: scotts-international.com

Technology

Category

Diagnostic device (portable food testing)

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

prototype

How it works

A miniaturised 'pocket laboratory' runs a rapid allergen assay on a food sample. The model is a reader plus single-use consumables, derived from bioMérieux diagnostic know-how.

Moat

Potentially strong: assay chemistry, miniaturisation know-how and bioMérieux's strategic involvement are hard to replicate; no patents are cited in the record.

Differentiation

Point-of-meal testing vs lab tests that take hours/days; diagnostic-grade pedigree vs consumer gadgets.

Integration points

  • Food brand QA processes
  • Restaurant HACCP/kitchen workflows
  • Consumer apps for allergy management

Depends on

  • Assay sensitivity/specificity validation
  • Consumable manufacturing cost
  • Food regulatory claims

Use of AI

No use of AI mentioned

Product in detail

Portable device for rapid detection of food allergens (miniaturized pocket-lab test).

Business

Model
Razor-and-blade: device plus recurring consumable tests (model inferred from 'hardware mini-lab + consumables').
Revenue logic
Revenue per test; B2B volume contracts with food service and brands.
Go-to-market
Early-adopter programme, then B2B channels (food service, brands) before consumers.

Next milestones

  1. Validated performance data vs lab reference
  2. First paying B2B early adopters
  3. Industrial consumable cost-down

Key risks

  • No commercial product
  • Uncertain consumer adoption
  • Accuracy, cost and adoption risk

Opportunities

4 found in the network

Concrete moves for Allergen Alert inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Customers 2
  • Co-development 1
  • Investors 1

Customers2

Who could buy, or sell through

Verified free-from claims for 'Food as Medicine' brands

Nuhpro sells functional foods targeting intolerances and digestive disorders, where trust in 'free-from' claims is the product. A portable allergen test lets Nuhpro verify batches and co-market verification to consumers, giving Allergen Alert an early B2B design partner.

35%confidence

Evidence from the records

  • “Functional food brands (SWEE-THY, PRO+PRO, FREEDA) sold B2C and B2B (Dealroom)”
  • “Portable mini-lab still in development (“early adopter” program, bioMérieux spin-off)”
If it works
A first branded use case and real-world validation data in free-from products.
First step
Invite Nuhpro into the early-adopter programme with a batch-verification protocol.

Allergen checks in unstaffed food service

Autonomous restaurants have no staff to answer allergen questions at the point of sale, so verified menu data is a liability control. Yo-Kai's 250+ ramen machines are a concentrated, multi-site test bed for B2B allergen verification of recipes.

20%confidence

Evidence from the records

  • “Autonomous restaurant / hot ramen vending machines”
  • “More than 250 ramen vending machines deployed (SFO, Tesla factories, Ueno station)”
If it works
A food-service reference with repeatable SKU testing.
First step
Propose a recipe-level allergen verification pilot on a handful of Yo-Kai SKUs.

Co-development1

An integration or joint product

Add AI signal interpretation to the pocket lab

Allergen Alert has no documented AI; MUI Robotics digitises sensory signals with AI for food quality control at Ajinomoto. Co-developing signal analytics and a food-industry data layer could improve reader accuracy and open Asian food-industry accounts.

25%confidence

Evidence from the records

  • “No use of AI mentioned”
  • “E-nose deployed at Ajinomoto, Double A and PTT (case studies)”
If it works
Better accuracy on complex matrices and an industrial channel in Asia.
First step
Set up a technical exchange on sensor data processing and food matrices.

Investors1

A fund whose thesis fits

EIC Accelerator for diagnostic deep tech

The EIC Fund takes strategic risk on European breakthrough MedTech/deep tech from seed, with tickets from $0.55M. Allergen Alert's pre-commercial, hardware-heavy profile is exactly the funding gap it targets; network members Lampsy Health and Leitspalt are EIC-backed and can share application experience.

35%confidence

Evidence from the records

  • “Close the funding gap for breakthrough technologies in Europe by taking strategic risk and crowding in private”
  • “Significant funding”
If it works
Blended grant-equity to finance validation and industrialisation without heavy dilution.
First step
Ask Lampsy Health for their EIC Accelerator application learnings and start the short proposal.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Xavier Niel's sector-agnostic Paris fund backing tech startups with French founders, in France or abroad, at pre-seed and seed.

French food-safety deep tech (bioMérieux spin-off) at seed — French team, strong tech.

45%confidence

Evidence from the records

  • “teams with an extraordinary learning and execution curve”
  • “Food allergen detection / food safety”
  • “Portable mini-lab still in development (“early adopter” program, bioMérieux spin-off)”
First step
Send a short deck directly.

European Innovation Council's Horizon Europe programme, funding deep-tech startups and SMEs with EIC Accelerator grants plus EIC Fund equity.

French portable allergen mini-lab in development: health and food-safety deep tech at prototype, an Accelerator-style scale-up step.

40%confidence

Evidence from the records

  • “Food allergen detection / food safety”
  • “Prototype”
Intro path
Leitspalt (EIC grantee)
First step
Apply to the EIC Accelerator for clinical/field validation.

'The French Tech Entrepreneurs' Fund': entrepreneur-backed Paris VC and growth investor from seed to buyout.

French bioMérieux spin-off for food allergen detection at seed — French deep tech with strong corporate backing.

40%confidence

Evidence from the records

  • “The French Tech Entrepreneurs' Fund”
  • “Food allergen detection / food safety”
  • “Portable mini-lab still in development (“early adopter” program, bioMérieux spin-off)”
Intro path
Founder-to-founder intro via ProcurePro (network portfolio company of ISAI).
First step
Ask Bpifrance (co-investor) for an introduction.

Korean food group's corporate investor; the only recorded deal is Yo-Kai Express's Series A, an automated ramen vending company.

Pocket lab that detects allergens in food: a food-safety technology a large food manufacturer could pilot or distribute.

40%confidence

Evidence from the records

  • “Food allergen detection / food safety”
  • “Portable mini-lab still in development”
Intro path
Co-investors bioMérieux, Bpifrance, Demeter.
First step
Propose a Pulmuone product-testing pilot.

Paris VC (~€1B AUM, 100+ startups) backing European-DNA tech with international ambition, pre-seed to Series A.

French portable allergen detection (bioMérieux spin-off) at seed: European food-safety deep tech; already backed by Bpifrance and Demeter.

35%confidence

Evidence from the records

  • “Food allergen detection / food safety”
  • “France”
Intro path
Bpifrance (co-investor network)
First step
Approach for the post-prototype round.

Amsterdam accelerator-VC with dedicated agrifood (€50M Fund II), energy and emerging-tech funds investing pre-seed and seed in Europe.

Lyon food-safety pocket lab; agrifood relevant but already backed by bioMérieux, Bpifrance and Demeter at seed.

30%confidence

Evidence from the records

  • “Food allergen detection / food safety”
  • “Seed”
First step
Explore a co-investment in Allergen Alert's next round.

Investment analysis

3.8D

Grade D

Rank 101 of 151

Disruption6.0/10
Business model2.0/10
Market3.0/10
Risk(lower is better)7.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Too early.

Disruption

6/10

Pocket laboratory for allergen detection: significant innovation.

Business model

2/10

Still in development, no sales.

Market

3/10

TAM food allergen testing ~$0.96bn (base 3), medium scalability 5/10 (0), no proven international expansion (0) → 3/10.

Risk

7/10

Lower is better

High risk: accuracy, cost and adoption, despite $3.9M raised.

Strengths

  • bioMérieux expertise
  • Significant funding

Risks

  • No commercial product
  • Uncertain consumer adoption

Funding

$3.9M, disclosed
  1. oct. 2025 (communiqué 9-14 oct. 2025)

    seedEUR 3.6M

    Demeter (FAIM Lyon/Saint-Étienne fund), bioMérieux, Bpifrance, private banks

Amount used in the study. Seed round of €3.6M including ~€900K in grants (Nordic9), with no double counting.

Note. EUR 3.6M (including ~EUR 900K in grants according to Nordic9)

verified, nothing to correct: win at the Aix-en-Provence stage (SWC France) confirmed, departure for San Francisco in November.

Team

  • Bénédicte Astier

    Founder & CEO

    20+ years in regulatory/quality at bioMérieux; master's in industrial pharmacy & business (emlyon).

  • Antoine Burgaud

    COO & Chief of Staff

    Doctor of pharmacy, emlyon graduate, ~10 years supporting healthtech/deeptech companies.

Sources

Regional final
France – Aix-en-Provence stage (Rencontres économiques d'Aix)
Identification confidence
high
Founding year: 2024 (high confidence)
Founded in October 2024 (bioMérieux spin-off, Messimy/Lyon) according to the press; SIREN not verified lejournaldesentreprises.com
  1. 1maddyness.com/?p=1439466

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet